YTHDF1 knockdown increased the sensitivity of breast cancer cells to Adriamycin, Cisplatin, and Olaparib (Fig. 4D) and promoted Adriamycin-induced cell apoptosis (Fig. 4E), indicating that YTHDF1 contributed to chemoresistance. Here, YTHDF1 is linked to breast cancer.